Exercise for Depression: Efficacy, Safety and Clinical Trial Implications
By Boadie W. Dunlop, Rachel L. Self
Psychopharmacology Bulletin. 2008;41(4):65–75.
Treatment Target in Schizophrenia: A Critical Review and a Clinical Suggestion
By Takefumi Suzuki, Hiroyuki Uchida, Koichiro Watanabe, Haruo Kashima
Psychopharmacology Bulletin. 2008;41(4):80–102.
Can Fluoxetine Alone Cause Serotonin Syndrome in Adolescents?
By Ahmad Ghanizadeh, MohammadJavad Ghanizadeh, Masoomah Seifoori
Psychopharmacology Bulletin. 2008;41(4):76–79.
Cessation of Cannabis Use by Patients with Recent-Onset Schizophrenia
and Related Disorders
By Nienke Dekker, MD, Lieuwe de Haan, MD, PhD, Sake van den Berg, MD, Martin de Gier, MD, Hiske Becker, MD, and Don H. Linszen, MD, PhD
Determinants of Complementary and Alternative Medicine Use by Patients with Bipolar Disorder
By Amy M. Kilbourne, PhD, MPH, Laurel A. Copeland, PhD, John E. Zeber, PhD, Mark S. Bauer, MD, Elaine Lasky, RN, and Chester B. Good, MD, MPH
Predicting Antipsychotic Use in Children
By Ken Gersing, MD, Bruce Burchett, PhD, JD, John March, MD, Truls Ostbye, MD, PhD, and K. Ranga Rama Krishnan, MD
Searching for the Puerperal Trigger: Molecular Genetic Studies of Bipolar Affective Puerperal Psychosis
By Ian Jones, MRCPsych, PhD, Nick Craddock, MRCPsych, PhD
Mood Stabilizers and Atypical Antipsychotics: Bimodal Treatments for Bipolar Disorder
By Terence A. Ketter, MD, Henry A. Nasrallah, MD, and Andrea Fagiolini, MD
A Model to Explain the Therapeutic Effects of Serotonin Reuptake Inhibitors: The Role of 5-HT2 Receptors
By Mikael Landén, MD, PhD, and Michael E. Thase, MD